Review article: Hepatitis C virus-associated steatosis - Pathogenic mechanisms and clinical implications

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 22, Issue 2, 2005, Pages 52-55

  Adinolfi, L E ^a   Durante Mangoni, E ^a   Zampino, R ^a   Ruggiero, G ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANTIVIRUS AGENT; CORE PROTEIN; INTERFERON; LIPOPROTEIN;

ATHEROSCLEROSIS; CLINICAL PATHWAY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FATTY LIVER; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERHOMOCYSTEINEMIA; INSULIN RESISTANCE; LIPID METABOLISM; LIVER CARCINOGENESIS; LIVER INJURY; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW;

EID: 27644551358     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02597.x     Document Type: Review

References (28)

1. Goodman ZD, Ishak KG. Histopathology of hepatitis C virus infection. Semin Liver Dis 1995; 15: 70-81.
2. Lefkowitch JH, Schiff ER, Davis GL, et al. Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group. Gastroenterology 1993; 104: 595-603.
3. Bach N, Thung SN, Schaffner F. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology 1992; 15: 572-7.
4. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004; 126: 586-97.
5. Adinolfi LE, Loria P, Lonardo A, Carulli N, Ruggiero G. Metabolic alterations in HCV-associated steatosis and in NAFLD: a comparison study. J Hepatol 2003; 38 (S2): 132 (Abstract 417).
6. Adinolfi LE, Utili R, Andreana A, et al. Relationship between genotypes of hepatitis C virus and histopathological manifestations in chronic hepatitis C patients. Eur J Gastroenterol Hepatol 2000; 12: 299-304.
7. Adinolfi LE, Utili R, Ruggiero G. Body composition and hepatic steatosis as precursors of fibrosis in chronic hepatitis C patients. Hepatology 1999; 30: 1530-1.
8. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-64.
9. Serfaty L, Andreani T, Giral P, Carbonell N, Chazouilleres O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001; 34: 428-34.
10. Kumar D, Farrell GC, Fung C, George J. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. Hepatology 2002; 36: 1266-72.
11. Negro F. Hepatitis C virus and liver steatosis: when fat is not beautiful. J Hepatol 2004; 40: 533-5.
12. Barba G, Harper F, Harada T, et al. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci U S A 1997; 94: 1200-5.
13. Shi ST, Polyak SJ, Tu H, et al. Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins. Virology 2002; 292: 198-210.
14. Perlemuter G, Sabile A, Letteron P, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J 2002; 16: 185-9.
15. Petit JM, Benichou M, Duvillard L, et al. Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis. Am J Gastroenterol 2003; 98: 1150-4.
16. Adinolfi LE, Ingrosso D, Cesaro G, Cimmino A, D'Anto M, Capasso R, Zappia V, Ruggiero G. Hyperhomocysteinemia and the MTHFR C677T polymorphism promote steatosis and fibrosis in chronic hepatitis C patients. Hepatology 2005; 41: 995-1003.
17. Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 2003; 125: 1695-704.
18. Adinolfi LE, Loria P, Lonardo A, et al. Prevalence and significance of insulin resistance in patients with NAFLD or chronic hepatitis C. Dig Liver Dis 2004; 36: A6.
19. Hourigan LF, Macdonald GA, Purdie D, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999; 29: 1215-9.
20. Castera L, Hezode C, Roudot-Thoraval F, et al. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsy. Gut 2003; 52: 288-92.
21. Leandro G, Mangia A, Hui J, et al. Steatosis is independently associated with fibrosis and necroinflammatory changes in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 2004; 40: s279A.
22. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38: 639-44.
23. Patton HM, Patel K, Behling C, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004; 40: 484-90.
24. Ohata K, Hamasaki K, Toriyama K, et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 2003; 97: 3036-43.
25. Caronia S, Taylor K, Pagliaro L, et al. Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 30: 1059-63.
26. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000; 133: 592-9.
27. Ishizaka N, Isizaka Y, Takahashi E, et al. Association between hepatitis C virus seropositivity, carotid-artery plaque and intima-media thickening. Lancet 2002; 359: 133-5.
28. Vassalle C, Masini S, Bianchi F, Zucchelli GC. Evidence for association between hepatitis C virus seropositivity and coronary artery disease. Heart 2004; 90: 565-6.